SynthesisFrontiers in pharmacology2025

Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations.

Hui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.